

Jay S Raval

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2315812/publications.pdf>

Version: 2024-02-01

100
papers

1,316
citations

331259

21
h-index

433756

31
g-index

103
all docs

103
docs citations

103
times ranked

1970
citing authors

#	ARTICLE	IF	CITATIONS
1	Autoantibody-Targeted Treatments for Acute Exacerbations of Idiopathic Pulmonary Fibrosis. PLoS ONE, 2015, 10, e0127771.	1.1	99
2	Pancreatic lymphoepithelial cysts express CEA and can contain mucous cells: potential pitfalls in the preoperative diagnosis. Modern Pathology, 2010, 23, 1467-1476.	2.9	64
3	Design of Asymmetric Particles Containing a Charged Interior and a Neutral Surface Charge: Comparative Study on <i>in Vivo</i> Circulation of Polyelectrolyte Microgels. Journal of the American Chemical Society, 2014, 136, 9947-9952.	6.6	46
4	Should All Massively Transfused Patients Be Treated Equally? An Analysis of Massive Transfusion Ratios in the Nontrauma Setting. Critical Care Medicine, 2017, 45, 1311-1316.	0.4	46
5	Use of a Massive Transfusion Protocol in Nontrauma Patients: Activate Away. Journal of the American College of Surgeons, 2013, 216, 1103-1109.	0.2	42
6	Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibody Titers in Convalescent Plasma and Recipients in New Mexico: An Open Treatment Study in Patients With Coronavirus Disease 2019. Journal of Infectious Diseases, 2020, 222, 1620-1628.	1.9	41
7	COVID-19 convalescent plasma: Interim recommendations from the AABB. Transfusion, 2021, 61, 1313-1323.	0.8	40
8	Innate Immune Activation After Transfusion of Stored Red Blood Cells. Transfusion Medicine Reviews, 2013, 27, 113-118.	0.9	39
9	Bortezomib induces clinical remission and reduction of ADAMTS13 inhibitory antibodies in relapsed refractory idiopathic thrombotic thrombocytopenic purpura. British Journal of Haematology, 2014, 164, 900-902.	1.2	38
10	Intravascular Talcosis due to Intravenous Drug Use Is an Underrecognized Cause of Pulmonary Hypertension. Pulmonary Medicine, 2012, 2012, 1-6.	0.5	37
11	Basal reactive oxygen species determine the susceptibility to apoptosis in cirrhotic hepatocytes. Free Radical Biology and Medicine, 2006, 41, 1645-1654.	1.3	33
12	Simultaneous extracorporeal membrane oxygenation and therapeutic plasma exchange procedures are tolerable in both pediatric and adult patients. Transfusion, 2014, 54, 1158-1165.	0.8	33
13	Cardiac Injury Is a Common Postmortem Finding in Thrombotic Thrombocytopenic Purpura Patients: Is Empiric Cardiac Monitoring and Protection Needed?. Therapeutic Apheresis and Dialysis, 2015, 19, 87-92.	0.4	30
14	Massive Transfusion. Archives of Surgery, 2012, 147, 563-71.	2.3	29
15	ADAMTS13: origins, applications, and prospects. Transfusion, 2018, 58, 2453-2462.	0.8	29
16	Extracorporeal photopheresis practice patterns: An international survey by the ASFA ECP subcommittee. Journal of Clinical Apheresis, 2017, 32, 215-223.	0.7	27
17	Anesthetic Management in Upper Extremity Transplantation. Anesthesia and Analgesia, 2012, 115, 678-688.	1.1	25
18	International assessment of massive transfusion protocol contents and indications for activation. Transfusion, 2019, 59, 1637-1643.	0.8	25

#	ARTICLE	IF	CITATIONS
19	Traumatic injury results in prolonged circulation of ultralarge von Willebrand factor and a reduction in <sc>ADAMTS13</sc> activity. <i>Transfusion</i> , 2020, 60, 1308-1318.	0.8	24
20	Contemporary issues in transfusion medicine informatics. <i>Journal of Pathology Informatics</i> , 2011, 2, 3.	0.8	23
21	Effect of blood bank storage on the rheological properties of male and female donor red blood cells. <i>Clinical Hemorheology and Microcirculation</i> , 2014, 56, 337-345.	0.9	22
22	Therapeutic plasma exchange and intravenous immune globulin in the treatment of <sc>heparin-induced</sc> thrombocytopenia: A systematic review. <i>Transfusion</i> , 2020, 60, 2714-2736.	0.8	22
23	Therapeutic Plasma Exchange in Myasthenia Gravis: A Systematic Literature Review and Meta-Analysis of Comparative Evidence. <i>Frontiers in Neurology</i> , 2021, 12, 662856.	1.1	22
24	Real-time monitoring of non-viable airborne particles correlates with airborne colonies and represents an acceptable surrogate for daily assessment of cell-processing cleanroom performance. <i>Cytotherapy</i> , 2012, 14, 1144-1150.	0.3	20
25	Bortezomib for Refractory Immune-Mediated Thrombocytopenia Purpura. <i>American Journal of Therapeutics</i> , 2018, 25, e270-e272.	0.5	19
26	United States Medical Licensing Examination Step 1 Two-Digit Score: A Correlation With the American Board of Pathology First-Time Test Taker Pass/Fail Rate at the University of Pittsburgh Medical Center. <i>Archives of Pathology and Laboratory Medicine</i> , 2011, 135, 1349-1352.	1.2	16
27	Effectiveness of an Algorithm-Based Approach to the Utilization of Plerixafor in Patients Undergoing Chemotherapy-Based Stem Cell Mobilization. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1064-1068.	2.0	16
28	Seasonal variability is not observed in the rates of high antiâ€A and antiâ€B titers in plasma, apheresis platelet, and whole blood units tested by different methods. <i>Transfusion</i> , 2019, 59, 762-767.	0.8	16
29	How we approach an acquired thrombotic thrombocytopenic purpura patient. <i>Transfusion</i> , 2014, 54, 2375-2382.	0.8	15
30	Implementation of a simple electronic transfusion alert system decreases inappropriate ordering of packed red blood cells and plasma in a multi-hospital health care system. <i>Transfusion and Apheresis Science</i> , 2014, 51, 53-58.	0.5	15
31	Viscoelastic testing in <sc>COVID</sc>â€19: a possible screening tool for severe disease?. <i>Transfusion</i> , 2020, 60, 1131-1132.	0.8	15
32	How do I manage longâ€term blood component shortages in a hospital transfusion service?. <i>Transfusion</i> , 2020, 60, 1897-1904.	0.8	15
33	Treatment of acquired Thrombotic Thrombocytopenic Purpura in the U.S. remains heterogeneous: Current and future points of clinical equipoise. <i>Journal of Clinical Apheresis</i> , 2018, 33, 291-296.	0.7	14
34	Transfusion of blood components containing ABO â€incompatible plasma does not lead to higher mortality in civilian trauma patients. <i>Transfusion</i> , 2020, 60, 2517-2528.	0.8	14
35	Development of a clinically significant ADAMTS13 inhibitor in a patient with hereditary thrombotic thrombocytopenic purpura. <i>American Journal of Hematology</i> , 2015, 90, E22.	2.0	13
36	Therapeutic plasma exchange for neuromyelitis optica spectrum disorder: A multicenter retrospective study by the ASFA neurologic diseases subcommittee. <i>Journal of Clinical Apheresis</i> , 2020, 35, 25-32.	0.7	13

#	ARTICLE	IF	CITATIONS
37	How do I implement an outpatient program for the administration of convalescent plasma for COVID-19?. <i>Transfusion</i> , 2022, , .	0.8	13
38	Race, rituximab, and relapse in TTP. <i>Blood</i> , 2022, 140, 1335-1344.	0.6	13
39	Plateletpheresis for postsplenectomy rebound thrombocytosis in a patient with chronic immune thrombocytopenic purpura on romiplostim. <i>Journal of Clinical Apheresis</i> , 2013, 28, 321-324.	0.7	11
40	Red blood cell transfusion in palliative care: what are we doing and why are we doing it?. <i>Transfusion</i> , 2018, 58, 3-4.	0.8	11
41	Von Willebrand factor as a thrombotic and inflammatory mediator in critical illness. <i>Transfusion</i> , 2020, 60, S158-S166.	0.8	11
42	Blood Product Transfusion in Adults: Indications, Adverse Reactions, and Modifications. <i>American Family Physician</i> , 2020, 102, 30-38.	0.1	11
43	Plasma exchange in a 13-year-old male with acute intravascular hemolysis and acute kidney injury after placement of a ventricular assist device. <i>Journal of Clinical Apheresis</i> , 2012, 27, 274-277.	0.7	10
44	Aged Human Stored Red Blood Cell Supernatant Inhibits Macrophage Phagocytosis in an HMGB1 Dependent Manner After Trauma in a Murine Model. <i>Shock</i> , 2017, 47, 217-224.	1.0	10
45	Extracorporeal photopheresis and personalized medicine in the 21st century: The future's so bright!. <i>Journal of Clinical Apheresis</i> , 2018, 33, 461-463.	0.7	10
46	Transfusion as a Palliative Strategy. <i>Current Oncology Reports</i> , 2019, 21, 92.	1.8	10
47	Therapeutic plasma exchange for management of heparin-induced thrombocytopenia: Results of an international practice survey. <i>Journal of Clinical Apheresis</i> , 2019, 34, 545-554.	0.7	10
48	Comparison of titer results obtained using immediate spin one dilution techniques to a reference method. <i>Transfusion</i> , 2019, 59, 1512-1517.	0.8	10
49	Transfusion of Uncrossmatched Group O Erythrocyte-containing Products Does Not Interfere with Most ABO Typings. <i>Anesthesiology</i> , 2020, 132, 525-534.	1.3	9
50	Does Early Ambulation Increase the Risk of Pulmonary Embolism in Deep Vein Thrombosis?. <i>Home Healthcare Nurse</i> , 2014, 32, 336-342.	0.4	8
51	Anti-D alloimmunization in Rh(D) negative adults with severe traumatic injury. <i>Transfusion</i> , 2021, 61, S144-S149.	0.8	8
52	The impact of suctioning RBCs from a simulated operative site on mechanical fragility and hemolysis. <i>The Korean Journal of Hematology</i> , 2011, 46, 31.	0.7	7
53	Seasonal distribution of severe ADAMTS13 deficient idiopathic thrombotic thrombocytopenic purpura. <i>Journal of Clinical Apheresis</i> , 2014, 29, 113-119.	0.7	7
54	Apheresis education in pathology residency. <i>Journal of Clinical Apheresis</i> , 2017, 32, 423-428.	0.7	7

#	ARTICLE	IF	CITATIONS
55	Biclonal IgD and IgM Plasma Cell Myeloma: A Report of Two Cases and a Literature Review. Case Reports in Hematology, 2013, 2013, 1-5.	0.3	6
56	Blood product transfusion and wastage rates in obstetric hemorrhage. Transfusion, 2018, 58, 1408-1413.	0.8	6
57	Therapeutic plasma exchange taper does not decrease exacerbations in immune thrombotic thrombocytopenic purpura patients. Transfusion, 2020, 60, 1676-1680.	0.8	6
58	Tolerance to incompatible ABO blood group antigens is not observed following homograft implantation. Human Immunology, 2011, 72, 835-840.	1.2	5
59	Taking Empiricism out of Immune Thrombotic Thrombocytopenic Purpura: Current and Future Treatment Strategies. Transfusion Medicine Reviews, 2019, 33, 248-255.	0.9	5
60	Massive Transfusion Protocol Activation Does Not Result in Preferential Use of Older Red Blood Cells. Journal of Blood Transfusion, 2014, 2014, 1-5.	3.3	4
61	Factor XIII Subunit A Immunohistochemical Expression is Associated With Inferior Outcomes in Acute Promyelocytic Leukemia. Applied Immunohistochemistry and Molecular Morphology, 2018, 26, 202-205.	0.6	4
62	Predictive Value of Schistocytes in Recurrence of Acquired Thrombotic Thrombocytopenic Purpura With Severe ADAMTS13 Deficiency at Discontinuation of Daily Therapeutic Plasma Exchange. Therapeutic Apheresis and Dialysis, 2018, 22, 662-665.	0.4	4
63	The top 10 things to know about transfusion medicine before intern year: an evidence-based course for graduating medical students. Blood Research, 2019, 54, 125-130.	0.5	4
64	A strategy to conserve personal protective equipment while performing therapeutic plasma exchange in a patient with COVID-19. Journal of Clinical Apheresis, 2020, 35, 374-375.	0.7	4
65	Changes in mechanical fragility and free hemoglobin levels after processing salvaged cardiopulmonary bypass circuit blood with a modified ultrafiltration device. Journal of Extra-Corporeal Technology, 2012, 44, 21-5.	0.2	4
66	Pathology Consultation on Electronic Crossmatch. American Journal of Clinical Pathology, 2014, 141, 618-624.	0.4	3
67	Monitoring therapeutic apheresis utilization: Database versus registry. Journal of Clinical Apheresis, 2017, 32, 208-209.	0.7	3
68	Blood product utilization in human upper extremity transplantation: challenges, complications, considerations, and transfusion protocol conception. Transfusion, 2017, 57, 606-612.	0.8	3
69	Heparin-induced thrombocytopenia associated with collection of hematopoietic progenitor cells by apheresis. Journal of Clinical Apheresis, 2020, 35, 59-61.	0.7	3
70	The report from ASFA COVID-19 taskforce: Considerations and prioritization on apheresis procedures during the SARS-CoV-2 coronavirus disease (COVID-19) pandemic. Journal of Clinical Apheresis, 2021, 36, 878-881.	0.7	3
71	Plasma Exchange Taper for Acquired TTP Is Protective Against Recurrence at Both 30 Days and 6 Months: A Retrospective Study from 2 Academic Medical Centers. Blood, 2015, 126, 1046-1046.	0.6	3
72	Lenalidomide-associated hemolytic anemia. Leukemia and Lymphoma, 2015, 56, 2717-2719.	0.6	2

#	ARTICLE	IF	CITATIONS
73	Registry development for thrombotic microangiopathies: Biting off more than can be chewed?. Journal of Clinical Apheresis, 2017, 32, 64-65.	0.7	2
74	Reprioritising transfusion medicine education for graduating medical students. Medical Education, 2017, 51, 1163-1164.	1.1	2
75	Interval decline in hemoglobin A is associated with annual clinical event rate in sickle cell anemia patients receiving maintenance apheresis RBC exchange. Transfusion, 2019, 59, 2622-2628.	0.8	2
76	Use of therapeutic plasma exchange for pediatric neurological diseases. Journal of Clinical Apheresis, 2021, 36, 161-176.	0.7	2
77	Acute hemolytic transfusion reaction attributed to anti-At^a. Immunohematology, 2016, 32, 140-142.	0.2	2
78	Differential Effect of Rituximab on Relapse-Free Survival in De Novo and Relapsed Immune Thrombotic Thrombocytopenic Purpura in African-American and Caucasian Populations. Blood, 2019, 134, 90-90.	0.6	2
79	African American Race Is Associated with Decreased Relapse-Free Survival in Immune Thrombotic Thrombocytopenic Purpura. Blood, 2019, 134, 1066-1066.	0.6	2
80	Vitamin K antagonist reversal strategies: Systematic review and network meta-analysis from the <sc>AABB</sc>. Transfusion, 2022, 62, 1652-1661.	0.8	2
81	Two cases of asymptomatic massive fetomaternal hemorrhage. Transfusion and Apheresis Science, 2015, 52, 208-210.	0.5	1
82	Rainbow of hemolysis associated with acquired thrombotic thrombocytopenic purpura. Journal of Clinical Apheresis, 2017, 32, 274-275.	0.7	1
83	Review of whole blood use in trauma. ISBT Science Series, 2019, 14, 282-288.	1.1	1
84	Critical developments of 2018: A review of the literature from selected topics in transfusion. A committee report from the AABB's Clinical Transfusion Medicine Committee. Transfusion, 2019, 59, 2733-2748.	0.8	1
85	Total plasma volume determinations for patients with potentially challenging conditions requiring therapeutic plasma exchange: Dealer's choice. Journal of Clinical Apheresis, 2020, 35, 138-139.	0.7	1
86	Adverse event reporting for cellular therapy products: Current status and future directions. Transfusion, 2020, 60, 2815-2827.	0.8	1
87	Current advances in transfusion medicine: a 2019 review of selected topics from the AABB Clinical Transfusion Medicine Committee. Transfusion, 2020, 60, 1614-1623.	0.8	1
88	Current advances in transfusion medicine 2020: A critical review of selected topics by the AABB Clinical Transfusion Medicine Committee. Transfusion, 2021, 61, 2756-2767.	0.8	1
89	Prolonged Circulation of Ultra-Large Von Willebrand Factor and a Reduction in ADAMTS13 Activity Promotes Microvascular Disease Following Traumatic Injury. Blood, 2019, 134, 444-444.	0.6	1
90	Mathematical modeling of the impact of recirculation on exchange kinetics in tandem extracorporeal membrane oxygenation and therapeutic plasma exchange. Journal of Clinical Apheresis, 2021, 36, 6-11.	0.7	1

#	ARTICLE	IF	CITATIONS
91	Complications following an unnecessary peri-operative plasma transfusion and literature review. The Korean Journal of Hematology, 2012, 47, 298.	0.7	0
92	Anesthetic Management in Upper Extremity Transplantation. Survey of Anesthesiology, 2013, 57, 207-208.	0.1	0
93	Complications following an unnecessary peri-operative plasma transfusion and literature review. Asian Journal of Transfusion Science, 2014, 8, 139.	0.1	0
94	Anesthesia and Perioperative Care in Reconstructive Transplantation. Anesthesiology Clinics, 2017, 35, 523-538.	0.6	0
95	The Impact of an Undergraduate Biology Class on Donor Recruitment at a Hospital-Based Blood Donor Center. American Journal of Clinical Pathology, 2020, 153, 368-373.	0.4	0
96	Heterogeneity of diagnosis, treatment, and management for immune thrombotic thrombocytopenic purpura: Are we still peering through the looking glass?. Journal of Clinical Apheresis, 2020, 35, 236-237.	0.7	0
97	Models for plasma kinetics during simultaneous therapeutic plasma exchange and extracorporeal membrane oxygenation. Mathematical Medicine and Biology, 2021, 38, 255-271.	0.8	0
98	A little heparin goes a long way: effect of therapeutic levels of unfractionated heparin on the heparin-induced thrombocytopenia-platelet factor 4 ELISA antibody assay. Blood Coagulation and Fibrinolysis, 2021, 32, 302-303.	0.5	0
99	Editorial: Thrombotic Microangiopathies, Diagnostic and Therapeutic Advances. Frontiers in Medicine, 2021, 8, 778352.	1.2	0
100	Acute hemolytic transfusion reaction attributed to anti-Ata. Immunohematology, 2016, 32, 140-142.	0.2	0